Mereo BioPharma Group plc Director/PDMR Shareholding (5582L)
27 December 2018 - 9:02PM
UK Regulatory
TIDMMPH
RNS Number : 5582L
Mereo BioPharma Group plc
27 December 2018
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PCA Dealing
London, 27 December 2018 - Mereo BioPharma Group plc (AIM: MPH),
a clinical stage UK based biopharmaceutical company focused on rare
diseases, received notification that on 21 December 2018, Eric
Scots-Knight, a person closely associated (PCA) with Denise
Scots-Knight, Chief Executive Officer of Mereo, purchased ordinary
shares of GBP0.003 each in the Company, as set out in the following
table.
The below announcement and notification is made in accordance
with the EU Market Abuse Regulation. The form required under the EU
Market Abuse Regulation follows.
DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND
THEIR CLOSELY ASSOCIATED PERSONS
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Eric Scots-Knight
------------------------ ---------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status PCA of Denise Scots-Knight, Chief Executive
Officer
------------------------ ---------------------------------------------
b) Initial notification Initial Notification
/ Amendment
------------------------ ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of Ordinary Shares of GBP0.003 each
the financial
instrument, type ISIN: GB00BZ4G2K23
of instrument
Identification
code:
------------------------ ---------------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------ ---------------------------------------------
c) Price(s) and 185 pence. 3000 Ordinary Shares of GBP0.003
volume(s) each
------------------------ ---------------------------------------------
d) Aggregated information 185 pence. 3000 Ordinary Shares of GBP0.003
each.
------------------------ ---------------------------------------------
e) Date of the transaction 21 December 2018
------------------------ ---------------------------------------------
f) Place of the London Stock Exchange
transaction
------------------------ ---------------------------------------------
Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated
Adviser and Broker) +44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Rupert Walford
Jamil Miah
FTI Consulting (Public Relations Adviser) +44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations
Advisor to Mereo Biopharma) +01 (0) 212 213 0006
Lisa Burns
Ami Bavishi
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for patients with rare diseases. Mereo's strategy
is to selectively acquire product candidates that have already
received significant investment from pharmaceutical companies and
that have substantial preclinical, clinical and manufacturing data
packages. In December 2018, Mereo announced the proposed
combination of Mereo and OncoMed Pharmaceuticals, with the
transaction expected to close in the first half of 2019. Each of
Mereo's four product candidates has previously generated positive
clinical data for Mereo's target indication or in a related
indication. Since inception Mereo has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for all four of the
product candidates:
-- BPS-804 for osteogenesis imperfecta (OI). The Company
recently announced completion of enrolment with 112 adult patients
in a Phase 2b dose ranging study with some initial data expected in
the H1 2019 and top-line dose ranging data in late 2019. A
pediatric Phase 3 study design has also been approved by the EMA.
BPS-804 has orphan designation in the US and EU and has been
accepted into the PRIME and Adaptive Pathways in EU;
-- MPH-966 for alpha-1 antitrypsin deficiency (AATD). The
Company recently announced first patient in in a Phase 2 dose
ranging study in the US with data expected in late 2019;
-- BCT-197 for acute exacerbations of COPD (AECOPD). The Company
announced positive top-line Phase 2 data in December 2017; and
-- BGS-649 for hypogonadotropic hypogonadism (HH). The Company
announced positive top-line Phase 2b data in March 2018 and
positive results in December 2018 from the safety extension to the
Phase 2b clinical trial.
-- As at September 30, 2018 Mereo had (unaudited) total cash
resources of approximately US$44.6 million
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKDLBLVLFEFBV
(END) Dow Jones Newswires
December 27, 2018 05:02 ET (10:02 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024